Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2009) Carolyn F. Deacon et al.   ADVANCES IN THERAPY

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

(2009) Abd A. Tahrani et al.   ADVANCES IN THERAPY

Comment on: Torii et al. (2009) Gene Silencing of Phogrin Unveils Its Essential Role in Glucose-Responsive Pancreatic  -Cell Growth. Diabetes 58:682-692

(2009) Y. Hu et al.   DIABETES

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

(2009) M. Jadzinsky et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

(2009) A. Fura et al.   DRUG METABOLISM AND DISPOSITION

Effect of Sitagliptin on the Pharmacokinetics of Simvastatin

(2009) Arthur J. Bergman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction

(2009) Robert V DiGregorio et al.   PHARMACOTHERAPY

Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004

(2008) Kwok Leung Ong et al.   ANNALS OF EPIDEMIOLOGY

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

(2008) Goutam C. Mistry et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review

(2008) Javaid H. Wani et al.   CARDIOLOGY CLINICS

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

(2008) R CHRISTOPHER et al.   CLINICAL THERAPEUTICS

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Looking to the Future Focus on DPP-4 Inhibitors for the Treatment of Type 2 Diabetes and Emerging Therapies

(2008) Joshua J. Neumiller et al.   DIABETES EDUCATOR

Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

(2008) R. Scott et al.   DIABETES OBESITY & METABOLISM

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

(2008) Viswanathan Mohan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

(2008) C. Pan et al.   DIABETIC MEDICINE

Vildagliptin

(2008) Jamie D Croxtall et al.   DRUGS

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

(2008) Bumsup Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Janumet™: a combination product suitable for use in patients with Type 2 diabetes

(2008) Jonathan Kent Reynolds et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Paget's Disease of the Mandible

(2008) Mayank B. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emergency Contraception: A Reasonable Personal Choice or a Destructive Societal Influence?

(2007) M F Greene   CLINICAL PHARMACOLOGY & THERAPEUTICS

Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?

(2007) J E Rossouw   CLINICAL PHARMACOLOGY & THERAPEUTICS

Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects

(2007) Yan-Ling He et al.   JOURNAL OF CLINICAL PHARMACOLOGY